Appendix A

Methods

Supplementary table 1. Overview of inclusion and exclusion criteria
Inclusion criteria
Fluent in English
Outpatient
≥ 18 years of age
BDDQ ≥ 4 at internet screening
DCQ ≥ 9 at internet screening
Primary diagnosis of BDD according to DSM-5
BDD-YBOCS ≥ 20
Verbal consent via video-conference and check yes to consent via treatment platform
Regular access to a computer with internet connection
Adequate skills to use the internet
Photo ID with name and age
Exclusion criteria
Psychotropic medication changes within 12 weeks prior to treatment
Completed CBT for BDD within 12 months prior to treatment
AUDIT ≥ 8 or DUDIT ≥ 8
Lifetime bipolar disorder or psychosis
MADRS-S ≥ 35
Clinically significant suicidal ideation or lifetime history or suicide attempts
Personality disorder that could jeopardize treatment participation (e.g. borderline personality disorder with self-harm)
Other current psychological treatment

No access to a 24 hour psychiatric emergency care center
No specific emergency contact person or emergency contact person phone number

Measures

Appearance Anxiety Inventory (AAI)

The AAI is a self-report, process measure that identifies cognitive processes and behaviors in the treatment of BDD. The maximum total score is 40, with higher scores indicating greater frequency of a process [1].

Brown Assessment of Beliefs Scale (BABS)

The BABS is a 7 item, clinician administered measure with excellent psychometric properties [2]. Scores can range from 0 to 24 with higher scores indicating poorer insight.

EuroQol – 5 Dimension Questionnaire (EQ-5D)

The EQ-5D is used as a non-disease specific assessment of quality of life and global functioning. It measures these constructs along 5 dimensions: Mobility, self-care, main activity, pain, and mood [3,4]. EQ-5D scores range between 0 (dead) and 1 (perfect health).

Sheehan Disability Scale (SDS)

The SDS has 3 items measuring functional impairment and disability regarding work/school, social life/leisure, and family life/home responsibilities on a likert scale between 0 (no interference) to 10 (extreme impairment). Two items measure days lost at work/school and days being underproductive at work/school. Items are on a likert scale of 0 (not at all) to 10 (very severe) [5,6].

Skin-Picking Scale – Revised (SPS-R)

The SPS-R is a self-report measure containing 8 items evaluating skin-picking severity. Scores range from 0 to 32 with higher scores indicating higher severity [7].

ICBT – EX/RP Adherence Scale

The ICBT – EX/RP Adherence Scale is modified from the Patient EX/RP Adherence Scale (PEAS) [8]. This measure assesses a patient's overall level of engagement in treatment with particular emphasis on quality and quantity of exposure and response prevention exercises. It looks at number of days, total hours, and quality of approach behaviors in EX/RP practice. In addition, it also looks other aspects of internet treatment adherence such as reading psychoeducational content and communicating with their therapist.

Results

Self-reported symptoms of BDD were significantly reduced over the course of treatment (F[13, 244.7] = 16.93, p <.001).

There were statistically significant reductions in delusionality on the BABS (F[2, 47.36] = 10.11, p < 0.001), as well as skin-picking using the SPS-R (F[2, 34.64] = 6.41, p = .004).

Changes in overall quality of life using the EQ-5D were not statistically significant (F[2, 36.28] = 1.35, p = .273). There were statistically significant improvements in functioning on the SDS (F[2, 35.07] = 12.78, p < .001).

Self-reported adherence to treatment (PEAS) increased over the course of treatment, from 16.83 (se = 1.88) at week 1, to 29.09 (se = 2.33) at post-treatmen

Supplementary table 2. Estimated means and change on secondary outcome measures

Outcome	Time	Estimated mean (SE)	Estimated change [95% CI]	d	p
AAI	Pre	26.66 (1.36)			
	Week 1	24.88 (1.11)	-1.78 [-3.95 to 0.39]	-0.26	0.109
	Week 2	22.25 (1.12)	-4.41 [-6.6 to -2.22]	-0.66	0.001
	Week 3	20.73 (1.14)	-5.93 [-8.16 to -3.69]	-0.88	0.001
	Week 4	19.09 (1.19)	-7.56 [-9.89 to -5.23]	-1.13	0.001
	Week 5	18.96 (1.15)	-7.69 [-9.95 to -5.43]	-1.14	0.001
	Week 6	18.52 (1.25)	-8.13 [-10.59 to -5.68]	-1.21	0.001
	Week 7	17.18 (1.28)	-9.48 [-11.98 to -6.97]	-1.41	0.001
	Week 8	17.47 (1.3)	-9.18 [-11.74 to -6.63]	-1.37	0.001
	Week 9	16.63 (1.28)	-10.03 [-12.53 to -7.53]	-1.49	0.001
	Week 10	16.86 (1.23)	-9.8 [-12.21 to -7.39]	-1.46	0.001
	Week 11	16.42 (1.37)	-10.23 [-12.91 to -7.56]	-1.52	0.001
	Post	14.38 (1.19)	-12.28 [-14.61 to -9.94]	-1.83	0.001
	Follow-up	13.45 (1.33)	-13.21 [-15.82 to -10.6]	-1.97	0.001
EQ-5D	Pre	0.75 (0.03)			
	Post	0.82 (0.04)	0.07 [-0.02 to 0.15]	0.33	0.126
	Follow-up	0.8 (0.05)	0.05 [-0.04 to 0.15]	0.25	0.302
SDS	Pre	14.56 (1.35)			
	Post	9.33 (1.43)	-5.17 [-7.93 to -2.41]	-0.6	0.001
	Follow-up	7.13 (1.6)	-7.43 [-10.57 to -4.29]	-0.86	0.001
SPS-R	Pre	6.38 (1)			
	Post	4.34 (0.74)	-2.03 [-3.49 to -0.58]	-0.33	0.01

	Follow-up	3.66 (0.85)	-2.72 [-4.38 to -1.06]	-0.44	0.003
PEAS	Week 1	16.83 (1.88)	-12.26 [-15.95 to -8.57]	-1.22	0.001
	Week 2	18.49 (1.91)	-10.6 [-14.33 to -6.86]	-1.05	0.001
	Week 3	24.83 (1.96)	-4.26 [-8.1 to -0.41]	-0.42	0.031
	Week 4	23.82 (1.98)	-5.27 [-9.15 to -1.39]	-0.52	0.008
	Week 5	26.62 (2.08)	-2.47 [-6.54 to 1.59]	-0.25	0.235
	Week 6	28.54 (2.1)	-0.55 [-4.68 to 3.57]	-0.06	0.793
	Week 7	29.22 (2.05)	0.13 [-3.9 to 4.16]	0.01	0.949
	Week 8	28.47 (2.07)	-0.63 [-4.68 to 3.43]	-0.06	0.763
	Week 9	28.19 (2.06)	-0.9 [-4.94 to 3.14]	-0.09	0.664
	Week 10	32.18 (2.18)	3.09 [-1.18 to 7.36]	0.31	0.157
	Week 11	36.1 (4.04)	7 [-0.91 to 14.92]	0.7	0.084
	Post	29.09 (2.33)			
WAI-SR	Week 2	43 (1.33)	-4.64 [-7.25 to -2.04]	-0.48	0.001
	Week 4	45.28 (1.34)	-2.37 [-4.99 to 0.25]	-0.25	0.08
	Week 6	46.02 (1.37)	-1.62 [-4.31 to 1.07]	-0.17	0.24
	Week 8	46.19 (1.38)	-1.45 [-4.16 to 1.26]	-0.15	0.296
	Week 10	46.75 (1.4)	-0.9 [-3.65 to 1.85]	-0.09	0.524
	Week 12	46.88 (2.53)	-0.77 [-5.73 to 4.2]	-0.08	0.763
	Post	47.65 (2.05)			
CSI	Pre	110.77 (5.72)			
	Post	124.27 (4.85)	13.49 [3.99 to 23]	0.43	0.011

Abbreviations: SE, standard error; CI, confidence interval; d, Cohen's d; p, p-value (estimated change); AAI, Appearance anxiety inventory; EQ-5D, EuroQol – 5 dimension questionnaire; SDS, Sheehan disability scale; SPS-R, Skin-picking scale – revised; PEAS, ICBT – exposure and response prevention adherence scale; WAI-SR, Working alliance inventory – short revised; CSI, Client satisfaction inventory.

Supplementary Figure 1. BDD-YBOCS



Supplementary Figure 2 - AAI and MADRS-S

Percentage change relative to baseline



Protocol

Karolinska Institutet

Therapist-Guided, Internet-Based Cognitive Behavioral Therapy for Body Dysmorphic Disorder – English Version (BDD-NET): A Feasibility Study

Principal Investigator: Christian Rück, MD, PhD, Department of Clinical Neuroscience

Version: XXXX

Date: XXXX

Table of Contents

1. Protocol Summary

PROTOCOL IDENTITY AND OBJECTIVES	
Protocol Title:	Therapist-Guided, Internet-Based Cognitive Behavioral Therapy for Body Dysmorphic Disorder – English Version (BDD-NET): A Feasibility Study
Trial Objectives:	Primary: Establish ICBT for BDD, English version (BDD-NET), as an acceptable, feasible, and potentially efficacious treatment.

METHODOLOGY	
Trial Design:	Uncontrolled clinical trial with within-subjects repeated measures design.
Treatment/Duration:	Internet-based cognitive behavioral therapy for 12 weeks.
Primary Endpoints:	Change from W0 to W12, 3 and 12-month follow-ups.
Efficacy Parameters:	Clinician-administered BDD-YBOCS[41]
Safety Parameters:	Designated emergency care centers, adverse events assessed weekly via the internet and also at post-treatment and 3-month follow-up using clinician assessments via video-conference or telephone.

POPULATION OF TRIAL SUBJECTS	
Description of Trial Subjects:	Adults, fulfill DSM-5 diagnostic criteria for BDD.
Number of Subjects:	30

TRIAL TIMETABLE	
First Subject In:	December 2015
Last Subject In:	January 2016
Last Subject Out:	April 2016

2. Administration Information

Principal Investigator: Christian Rück, MD, PhD

Phone	+46 704.84.33.92
Email	Christian.ruck@ki.se
Address	M46 Internetpsykiatrienheten. SE-141 86 Stockholm, SE

Project manager: Christopher La Lima, MA

Phone	XXXX
Email	Christopher.la.lima@ki.se
Address	M46 Internetpsykiatrienheten. SE-141 86 Stockholm, SE

PERSONNEL INFORMATION

Personnel	Background	Role	Affiliation
Christopher La Lima, MA	Clinical Psychology PhD student at Hofstra University	Co-Investigator, Project Manager	Karolinska Institutet (KI) and Hofstra University
Christian Rück, MD, PhD	Psychiatrist, associate professor, senior lecturer. Co-founder of Internetpsykiatrienheten, the world's largest implementation of ICBT in mental health. Research group leader in a group specializing in ICBT for OCD, BDD, and related disorders (www.rucklab.com)	Principal Investigator	KI
Jesper Enander, MSc	Doctoral candidate, psychologist, KI. Has written the ICBT program for BDD (BDD-NET).	Development and monitoring psychological treatment, IT platform	KI
Sabine Wilhelm, PhD	Chief of Psychology, Massachusetts General Hospital (MGH) Director, OCD and Related Disorders Program, MGH Professor, Harvard Medical School	Treatment development, recruitment, design	Harvard, MGH
David Mataix-Cols, PhD	Professor at KI. The most cited European researcher in OCD and related disorders (ISI Web of Science).	Supervising, study design	KI

3. Research field overview

WHAT IS BDD?

Body Dysmorphic Disorder (BDD) is a disabling illness characterized by excessive preoccupation with minor or imagined defect(s) in one's physical appearance, followed by

repetitive behaviors (e.g. mirror checking, camouflaging, mentally comparing one's appearance to another) and avoidance. This preoccupation leads to clinically significant distress and/or impairment[1]. BDD is associated with decreased social, emotional, and occupational functioning, as well as reduced quality of life[2, 3]. It is a chronic disorder linked to high rates of hospitalization[3, 4]. Individuals with BDD tend to have elevated rates of suicidal ideation and suicide attempts[5-7]. Furthermore, preliminary results suggest that they have a higher rate of completed suicide[6].

BDD is a prevalent disorder, affecting 0.7 % to 2.4 % of the general population across a variety of nationalities and geographic locations[7-12]. Specifically, it has a point prevalence of 2.4 % in the United States, exceeding schizophrenia and bipolar I disorder, and 2.1% among Swedish women[8, 9]. Additionally, BDD is a heritable disorder, with genetic factors accounting for approximately 44% of the variance in dysmorphic concerns[13].

While relatively common, many individuals with BDD are not receiving proper treatment. BDD is underdiagnosed in mental health care settings, and patients often do not express body image concerns to physicians due to feelings of shame[5, 14, 15]. Furthermore, individuals with BDD often have poor insight and seek non-psychiatric care, such as dermatological treatments and cosmetic surgery. Such treatments are rarely effective and can lead to a worsening of symptoms[16-18].

CBT FOR BDD

Evidence based treatments for BDD include cognitive behavioural therapy (CBT) and pharmacotherapy with serotonin reuptake inhibitors (SRIs)[19-22]. Veale et al. (2014) conducted the only RCT comparing CBT with an active comparison group to date. They reported superiority of CBT over anxiety management, including progressive muscle relaxation and breathing techniques. Wilhelm et al. (2013) developed a multimodal treatment manual for BDD that was tested in one open trial and one wait-list controlled trial. Both studies resulted in improved BDD symptoms at post-treatment and maintained gains at a 6-month follow-up[21, 23]. Wilhelm et al. (2014) additionally found that depression, insight, and disability significantly improved with this treatment. These studies show promising results that CBT is effective and can have a lasting effect on symptom reduction in the months following treatment. However, to date there are relatively few studies of CBT treatment for BDD, and they include relatively small samples, so larger studies are needed to better understand this area.

While studies of CBT for BDD suggest that this treatment is efficacious, few patients are in fact receiving it[24]. In an online survey, 17.4% of participants diagnosed or self-diagnosed with BDD had received empirically supported psychotherapy (i.e. CBT) for body dysmorphic concerns, and 34.4% had been treated with SSRIs[25]. In another internet survey, 19.8% of people with body dysmorphic concerns were participating in psychosocial treatment, and 18.6% were receiving psychotropic medications[24]. Participants in both studies reported that shame associated with talking openly about one's appearance concerns was a major factor in not seeking help. In addition to underreporting symptoms associated with shame, underdiagnosis of BDD in mental health settings, and patients seeking non-psychiatric treatments that are ineffective or potentially worsen symptoms, individuals face restricted access to CBT[5, 14, 15, 16-18, 25-27]. This includes cost of services, a lack of trained therapists, and not having a specialized healthcare provider

nearby[25-27]. Furthermore, scheduling difficulties and transportation to healthcare providers hinder help-seeking efforts[25]. Therefore, it is clear that improved access to CBT treatments is needed.

ICBT FOR BDD

In response to limited CBT availability and accessibility, internet-based CBT (ICBT) with therapist support has been developed. In ICBT, the patient, instead of going to a clinic, logs onto a secure website and works with written self-help materials and homework assignments, supported online by a clinician. It has the advantage of being more accessible and requiring less therapist time than face-to-face[28]. ICBT has been shown to be effective in treating a variety of psychiatric disorders, such as obsessive-compulsive disorder, social anxiety disorder, depression, and panic disorder[29-31]. When compared to face-to-face CBT, a recent meta-analysis suggests no difference in treatment outcomes between the two, although there might be disorder-specific differences[32]. Additionally, ICBT is cost-effective and has been employed as a part of healthcare systems in Sweden, Australia, and the Netherlands[30, 32-36].

Recently, members of our research group (Enander et al. 2014)[37] developed ICBT for BDD (BDD-NET), based on existing BDD CBT manuals[38, 39], and tested it with a Swedish-speaking sample in an uncontrolled clinical trial. Results indicated BDD-NET was effective, with 82% of participants responding to treatment and large effect sizes. Participants also showed improvement in the areas of depression, skin picking, global functioning, and body image-related quality of life. Treatment gains in this study were maintained at a 3-month follow-up, and ICBT for BDD was highly accepted by participants[37]. Additionally, therapist interaction time was lower than that of typical CBT. Enander et al. (2015)[40] then conducted an RCT comparing BDD-NET with an active control (supportive therapy). In this trial, BDD-NET was superior to supportive therapy and associated with significant improvements in symptom severity, depression, and quality of life (submitted manuscript). Furthermore, self-reported satisfaction with BDD-NET was high.

ICBT for BDD may be especially important to address restricted access to treatment, including therapist availability, costs of services, and proximity to a clinician with specialized training. In addition, patients with BDD who have difficulties seeking face-to-face care may be easier reached via the internet. To test the BDD ICBT protocol (BDD-NET) in an English-language adaptation may be a first step to greatly increasing the availability of evidence-based treatment in the United States, Great Britain, India, and other areas with English-speaking populations. The current study aims to do just that in a pilot trial.

4. Purpose and Objectives

GENERAL PURPOSE

We plan to establish ICBT for BDD, English version (BDD-NET), as an acceptable, feasible, and potentially efficacious treatment for English-speakers across national borders. To achieve these goals, we need to:

PRIMARY OBJECTIVES

O1: Gain evidence that BDD-NET with therapist support leads to decreased symptoms of BDD.
O2: Assess patient satisfaction with the BDD-NET treatment platform and online therapist guidance.

O3: Evaluate patient engagement and ability to utilize tools and services offered in BDD-NET.

RESEARCH QUESTIONS
Q1: Does BDD-NET lead to a decrease in BDD symptom severity, dysmorphic concerns, and appearance concerns in English-speaking patients diagnosed with BDD?
Q2: Does BDD-NET improve insight/delusionality in these patients?
Q3: Does BDD-NET reduce symptoms of depression in these patients?
Q4: Does BDD-NET improve global functioning, quality of life, and disability in these patients?
Q5: Are these patients satisfied with BDD-NET and do they report a good working alliance with BDD-NET therapists?
Q6: Do these patients see BDD-NET as a credible intervention?
Q7: Are these patients compliant with the BDD-NET treatment protocol and able to complete treatment behaviors with its given resources?
Q8: Does the completion of EX/RP exercises and/or other treatment behaviors in BDD-NET predict outcome?

5. Hypotheses

H1. English-speakers diagnosed with BDD will decrease their BDD symptom severity, dysmorphic concerns, and appearance concerns at the end of the BDD-NET program (week 12), and at 3 and 12 month follow-ups, as compared to pretreatment.
H2. These patients will improve in insight/delusionality at week 12, and 3 and 12 month follow-ups, as compared to pretreatment.
H3. These patients will reduce in depression symptoms at week 12, and 3 and 12 month follow-ups, as compared to pretreatment.
H4: These patients will improve in global functioning, quality of life, and disability at week 12, and 3 and 12 month follow-ups, as compared to pretreatment.
H5: These patients will report satisfaction with treatment at W2, W7, and W12, and good working alliance with therapists.
H6: These patients will report treatment credibility for BDD-NET throughout treatment.
H7: These patients will complete BDD-NET core treatment modules (1-5) within 12 weeks of treatment, including module homework questions, written worksheets, and monitoring completed EX/RP exercises, provided BDD-NET resources and online therapist guidance.
H8: Reported EX/RP behaviors throughout treatment will predict outcome, with more EX/RP practice leading to greater improvement.

6. Endpoints

PRIMARY ENDPOINT

H	Measure	Utility	Time Points by Week															
			S	0	1	2	3	4	5	6	7	8	9	10	11	12	Post (12)	3m	12m
H1	Clinician-rated Body Dysmorphic Disorder	BDD symptom severity		x						x							x	x	x

	Modification of Y-BOCS; BDD-YBOCS[41]																	

SECONDARY ENDPOINTS

H	Measure	Utility	Time Points by Week															
			S	0	1	2	3	4	5	6	7	8	9	10	11	12	Post (12)	3m	12m
	Structured Clinical Interview for DSM 5 – Research Version (SCID-5-RV) module G[42]	BDD Remission status, comorbid anxiety diagnoses (e.g. social phobia)		x													x	x	x
	Mini-International Neuropsychiatric Interview – version 7.0 (M.I.N.I. 7.0)[43]	Current major depressive episode, comorbid diagnoses		x													x	x	x
H1	Dysmorphic Concerns Questionnaire (DCQ)[44]	BDD screening/ dysmorphic concerns	x	x													x	x	x
H1	Appearance Anxiety Inventory (AAI)[45]	BDD symptoms	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
H2	Brown Assessment of Beliefs Scale (BABS)[46]	Conviction and insight regarding beliefs/ obsessions		x													x	x	x
H3	Montgomery-Åsberg Depression Rating Scale, self-report (MADRS-S)[47]	Depressive symptoms	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
	Columbia-Suicide Severity Rating Scale (C-SSRS)	Suicide severity, suicidal		x													x	x	x

	Lifetime Recent – Clinical Version[48]	ideations and behaviors																	
	Skin-Picking Scale – Revised (SPS-R)[49]	Skin-picking severity		x												x	x	x	
H4	Global Assessment of Functioning (GAF)[50]	Global functioning		x												x	x	x	
H4	Clinical Global Impressions Scale – Severity (CGI-S)[51]	Global severity		x												x	x	x	
H4	Clinical Global Impressions Scale – Improvement (CGI-I)[51]	Global Improvement														x	x	x	
H4	EuroQol – 5 Dimension Questionnaire (EQ-5D)[52]	Quality of life		x												x	x	x	
H4	Sheehan Disability Scale (SDS)[53]	Functional Impairment		x												x	x	x	
H5	Client Satisfaction Inventory (CSI)[54]	Client satisfaction				x					x					x			
H5	Working Alliance Inventory – Short Revised (WAI-SR)[55]	Therapeutic alliance				x		x		x		x		x		x	x		
H6	Credibility Scale (Credibility/Expectancy Questionnaire)[56]	Treatment Credibility and expectancy		x		x		x		x		x		x		x	x		
H7	Completion of core treatment modules (1-5)	Treatment compliance	Continually monitored throughout treatment																
H7	Early Termination Checklist (Appendix Figure 1)	Reasons for early discontinuation or withdrawal	Continually monitored throughout treatment																

H8	ICBT – EX/RP Adherence Scale (modified from the Patient EX/RP Adherence Scale (PEAS)[57])	EX/RP adherence and practice; treatment adherence				x	x	x	x	x	x	x	x	x	x	x	x	

7. Efficacy of Data Collection

CLINICIAN-ADMINISTERED INTERVIEWS AND MEASURES

Clinician-Rated Body Dysmorphic Disorder Modification of Y-BOCS (BDD-YBOCS)[41]. The BDD-YBOCS is a modification of the Yale-Brown Obsessive Compulsive Scale designed to rate BDD symptom severity. It is a 12-item, semi-structured, clinician-administered interview with a total score of 0-48. Higher scores indicate more severe BDD symptoms[41]. In a recent study examining the psychometric properties of the BDD-YBOCS, it was found to have excellent interrater intra-class correlation coefficients (ICC), [.77 to 1.00 (p's < .001)] on all items, good test-retest ICCs for individual items [.73 to .93 (p's < .001)], and strong internal consistency [Cronbach's $\alpha = .92$][41].

Structured Clinical Interview for DSM 5 – Research Version (SCID-5-RV), module G[42]. The SCID-5-RV is a semi-structured, clinician-administered interview designed to diagnose disorders according to the DSM-5[42]. For the purposes of the present study, only module G (obsessive-compulsive and related disorders) will be utilized.

Mini-International Neuropsychiatric Interview – Version 7.0 (M.I.N.I. 7.0)[43]. The M.I.N.I. 7.0 is a reliable and valid, brief, structured diagnostic assessment administered by a clinician[43]. It covers a range of disorders, including Agoraphobia, Alcohol Dependence/Abuse, Anorexia Nervosa, Antisocial Personality Disorder, Bulimia Nervosa, Generalized Anxiety Disorder, (Hypo) Manic Episode / Bi-Polar Disorder, Major Depressive Episode, Obsessive Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Psychotic Disorders, Social Phobia (Social Anxiety Disorder), Substance Dependence/Abuse, and Suicidality[43]. This instrument will be used to screen and assess comorbid disorders and co-occurring pathology.

Columbia-Suicide Severity Rating Scale (C-SSRS) Lifetime Recent – Clinical Version[48]. The C-SSRS was designed to assess the severity of suicidal thoughts and behaviors. The C-SSRS has good convergent, divergent, and predictive validity, as well as sensitivity and specificity[48]. The ideation and behavior subscales show strong convergent validity with established suicidal ideation and behavior scales. In this study, exclusion during the W0 screen is based on a Most Severe Ideation score ≥ 4 (Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts) in the past month, or any reported lifetime actual attempt, interrupted attempt, aborted attempt, or preparatory behavior for suicide[48].

Global Assessment of Functioning (GAF)[50]. The GAF is a clinician rating of 1 to 100 indicating a patient's overall level of functioning. A higher score indicates greater functioning[50].

Clinical Global Impressions Scale - Severity (CGI-S)[51]. The CGI-S is a clinician global rating of a patient's overall severity. It ranges from 1 (normal, not ill at all) to 7 (among the most extremely ill of subjects)[51].

Clinical Global Impressions Scale – Improvement (CGI-I)[51]. The CGI-I is a clinician global rating of a patient's overall symptom change. It ranges from 1 (very much improved) to 7 (very much worse)[51].

SELF-REPORT MEASURES

Body Dysmorphic Disorder Questionnaire (BDDQ)[58]. The BDDQ is a BDD screening tool with good sensitivity and specificity[15]. A BDDQ cut-off score of at least 4 (positive BDD-screening) will be used to screen eligible participants for this study[59].

Dysmorphic Concerns Questionnaire (DCQ)[44]. The DCQ is a 7-item questionnaire assessing dysmorphic concerns in which patients compare their degree of concern with that of others for each item. It has good internal consistency (Cronbach's $\alpha = .88$), and strong correlations with other measures of distress and work and social impairment[44]. A DCQ cut-off score of 9 will be used to determine a positive BDD screen following the initial internet screening, as it has been shown to correctly identify 96.4% of BDD patients and 90.6% of undergraduates[60].

Brown Assessment of Beliefs Scale (BABS)[46]. The BABS is a clinician-administered, 7-item scale designed to assess delusional beliefs and insight in a range of psychiatric disorders. Total scores range from 0 to 24, with higher scores indicating greater delusionality or lack of insight. This instrument has good internal consistency (Cronbach's $\alpha = .87$), test-retest reliability (individual item test-retest ICCs = .79-.98, median = .95), interrater reliability (ICC = .96), and sensitivity to change, and very good convergent validity[46]. There is evidence to suggest that a score of 4 on the first item (conviction) in addition to a total score of at least 18 out of 24 is an empirically supported criteria for classifying a patient's beliefs as delusional[46].

Appearance Anxiety Inventory (AAI)[45]. The AAI was designed to be a process measure that identifies cognitive processes and behaviors possibly mediating outcome in the treatment of BDD[45]. It consists of 10 self-report items, each scored on a 5-point Likert scale ranging from 0 (not at all) to 4 (all the time). The maximum total score is 40, with higher scores indicating greater frequency of a process[45]. It has good internal consistency (Cronbach's $\alpha = .86$), test-retest reliability (ICC = .87, $p < .001$), convergent validity for the measurement of appearance anxiety, and sensitivity to change[45].

Skin-Picking Scale – Revised (SPS-R)[49]. The SPS-R is a self-report measure containing 8 items evaluating skin-picking disorder severity. It has acceptable internal consistency for the total score (Cronbach's $\alpha = .83$), as well as the symptom severity (Cronbach's $\alpha = .81$) and impairment (Cronbach's $\alpha = .79$) subscales[49]. Preliminary evidence supports convergent/concurrent and discriminant validity for the 2 subscales[49].

Montgomery - Åsberg Depression Rating Scale – self-report (MADRS-S)[47]. The MADRS-S contains 9 items evaluating depressive symptoms. It has satisfactory test-retest reliability and internal consistency (ICC = .78, Cronbach's alpha = .84), and good sensitivity to change[61]. It correlates well with the Beck Depression Inventory (BDI) [$r = .87$ ($p < .0001$)][62]. Holländare, Andersson, and Engström (2010) found a high correlation between total scores on the MADRS-S paper and internet versions [$r = .84$ ($p < .001$)][63]. Additionally, their results indicated no significant main effect for administration format between paper and internet versions. The MADRS-S was found to have good discriminative validity with the physician-rated Montgomery - Åsberg Depression Rating Scale (MADRS) in detecting a score of at least 35 (severe) during a current depressive episode[61].

Client Satisfaction Inventory (CSI)[54]. The CSI contains 25 items evaluating overall satisfaction with treatment. Total scores on this measure range from 0 % to 100 % satisfied. It is reliable, with very good internal consistency (Cronbach's $\alpha = .93$), and a standard error of measurement less than 5 % of the full range of scores[52]. Additionally, there is evidence to support good content and construct validity (μ item-total $r = .57$)[54].

Working Alliance Inventory – Short Revised (WAI-SR)[55]. The WAI-SR measures 3 aspects of therapeutic alliance: agreement on the tasks of therapy, agreement on the goals of therapy, and development of an affective bond. The WAI-SR correlates well with the original Working Alliance Inventory total score (r = .94-.95), as well as other alliance measures[55].

Credibility/Expectancy Questionnaire[56]. The Credibility/Expectancy Questionnaire is divided into 2 subscales that assess beliefs about the credibility of a treatment and thoughts/feelings of treatment expectancy. It was found to have a high internal consistency across 3 studies (expectancy factor standardized α = .79-.90; credibility factor Cronbach's α = .81-.86; whole scale standardized α = .84-.85). Additionally, it had good test-rest reliability over the course of 1 week (expectancy: .82, credibility: .75)[56].

EuroQol – 5 Dimension Questionnaire (EQ-5D)[52]. The EQ-5D is used as a non-disease specific assessment of quality of life and global functioning. It measures these constructs along 5 dimensions: Mobility, self-care, main activity, pain, and mood, and has shown some evidence for construct validity and good test-retest reliability[52, 64].

Sheehan Disability Scale (SDS)[53]. The SDS is a 4-item questionnaire measuring functional impairment and disability. Items 1-3 assess the domains of disability regarding work, social life and leisure, and family life and home responsibilities. They are on a likert scale of 0 (not at all) to 10 (very severe). Item 4 measures overall impairment and is on a likert scale of 1 (no symptoms) to 5 (symptoms radically change or prevent normal work or social life). In a study conducted by Leon, Olfson, Portera, Farber, and Sheehan (1997), this instrument was found to have high internal consistency (Cronbach's α = .89) and good construct validity, with over 80 % of patients with psychiatric disorders having an elevated SDS score[53].

ICBT – EX/RP Adherence Scale (modified from the Patient EX/RP Adherence Scale (PEAS)[57]). The ICBT EX/RP Adherence Scale is loosely based on the Patient EX/RP Adherence Scale (PEAS)[57]. It is a questionnaire designed for this study measuring number of days in which EX/RP was practiced, total hours EX/RP was conducted, quality of approach behaviors (1, (Didn't do exposure, 0% approach/100% avoidance) to 7 (Most, > 90%)) and ritual prevention (0, (0% response prevention) to 7 (Most > 90%)) during planned EX/RP practice, and quality of approach behaviors and ritual prevention outside of planned EX/RP practice in the past week. It also assesses number of days and total hours in which other ICBT treatment behaviors were completed in the past week (E.g. messaging therapist and reading psychoeducational materials).

BEHAVIORAL OUTCOME DATA

Completion of core treatment modules (1-5). Modules 1-5 contain the core components of treatment (psychoeducation, EX/RP hierarchy formation, cognitive restructuring, and EX/RP practice). Patients will be granted access to subsequent modules after completion of the previous one unless otherwise clinically indicated. In order to consider a module completed, subjects must provide written text relevant to symptoms, concerns, and treatment, according to module prompts, for all module homework assignments and written worksheets, as well as monitor their SUDS levels related to EX/RP practice.

Treatment termination (as measured by the Early Termination Checklist). The Early Termination Checklist is to be completed by the therapist of each subject immediately following early discontinuation for any reason. It provides the reason(s) for ending treatment prematurely, whether related to early termination or voluntary withdrawal.

8. Project description

DESIGN

A pilot study with within-subjects repeated measures design. Analysis of primary (BDD-YBOCS[41]) and secondary outcome measures between baseline and post treatment will be conducted to determine if the treatment significantly reduced symptoms associated with BDD. In a comparable study using a Swedish-language version of BDD-NET, Enander et al. (2014) [N = 23] found effect sizes of $d = 2.01$ ($p < .01$) at post-treatment and $d = 2.04$ ($p < .01$) at a 3-month follow-up, with 82% of completers being responders (≥ 30% decrease on the BDD-YBOCS)[37]. Furthermore, Enander et al. (2015) [N = 94] had effect sizes of .95 ($p < .001$) and .87 ($p < .001$) at post-treatment and 3-month follow-up, respectively, in an RCT comparing BDD-NET to supportive therapy[40]. Given 80% power, 30 participants are needed to be able to detect an effect size of $d = 0.66$. Clinical assessments of treatment effects and feedback from participants will be utilized to improve upon the BDD-NET treatment protocol.

SELECTION, WITHDRAWAL, AND DISCONTINUATION OF SUBJECTS

INCLUSION CRITERIA

Criteria	Method of Ascertainment
1. Fluent in English	Video-conference inclusion evaluation. If English is not subject's native language, he/she will be asked to read through 1 page of non-CBT treatment text and follow prompts; assessment based on the judgment of the evaluator
2. Outpatient	Self-report
3. At least 18 years of age	Self-report
4. Positive screening for BDD on BDDQ[58]	BDDQ score ≥ 4 at initial internet screening[59]
5. Positive screen for BDD on DCQ[44]	DCQ score ≥ 9 at initial internet screening[44]
6. Primary Diagnosis of BDD according to DSM-5[1]	SCID-5 module G[42]
7. A score of at least 20 on the BDD-YBOCS at baseline[41]	BDD-YBOCS[41]
8. Signed Informed Consent	Verbal consent via video-conference and check yes to consent on secure webpage
9. Regular access to a computer with internet capabilities	BDD-NET Accessibility and Confidentiality Interview
10. Adequate skills to use the internet	Self-report, completion of initial internet screening
11. Photo ID with name and age	Shown via video-conference at inclusion evaluation

EXCLUSION CRITERIA

Criteria	Method of Ascertainment
1. Psychotropic medication changes within 12 weeks prior to treatment	Self-report
2. Completed CBT for BDD within 12 months prior to treatment (defined as at least 12 sessions of EX/RP)	Self-report
3. Current substance dependence	Alcohol Use Disorders Identification Test (AUDIT) score ≥ 8[65], Drug User Disorders Identification Test (DUDIT) score ≥ 8[66], Mini-International Neuropsychiatric Interview – version 7.0 (M.I.N.I. 7.0)[43]
4. Lifetime bipolar disorder or psychosis	Self-report and M.I.N.I. 7.0[43]
5. Severe Depression	MADRS-S[47] score ≥ 35
6. Clinically significant suicidal ideation or lifetime history of suicide attempts	Video-conference inclusion evaluation; ≥ 5 on item 9 of MADRS-S[47]; C-SSRS Lifetime Recent – Clinical Version: Recent (past month) - Most Severe Ideation score ≥ 4, or any lifetime actual attempt, interrupted attempt, aborted attempt, or preparatory behavior for suicide[48].
7. Personality disorder that could jeopardize treatment participation (e.g. borderline personality disorder with self-harm)	PD diagnosis based on self-report and video-conference inclusion evaluation.
8. Other current psychological treatment	Self-report
9. No access to a 24 hour psychiatric emergency care center	Self-report; Co-investigator will confirm access based on subject's location and contact with emergency care center
10. No specified emergency contact person or emergency contact person phone number	BDD-NET Safety Interview

CRITERIA FOR WITHDRAWAL

1. Consent withdrawal by patient.
2. High suicide risk determined by the investigators.
3. Attempt at suicide during treatment.
4. Worsening of BDD symptoms better addressed by treatment incompatible with this protocol, as determined by the investigators' clinical judgment.
5. Psychiatric hospitalization during treatment.

OTHER REASONS FOR PREMATURE DISCONTINUATION OF TREATMENT

1. Adverse event or circumstances justifying the discontinuation of treatment as determined by the investigators.

2. Protocol deviation that jeopardizes the patient's safety.
3. Patient lost to follow-up: In the event that a patient is non-responsive following treatment, the investigators are to make efforts to contact him/her, establish a reason for discontinuation of treatment, and suggest the subject participate in an end-of-study video-conference interview. If these attempts to contact the participant fail, the investigators declare him/her "lost to post-treatment assessment." The previous contact attempts should be documented in the patient's medical file.

SUBJECT LOG

- The investigators must record the reason and date of premature discontinuation of treatment both in Take Care (electronic medical records system) and on the Early Termination Checklist (Appendix Figure 1). If the investigator gives more than one reason, he/she must indicate the main reason. Specifically if a subject withdraws, his/her therapist will ask him/her the reason for withdrawal.
- In the case of treatment discontinuation, participants will be asked to participate in all remaining scheduled assessments, including all measures for weekly internet self-reports and video-conference interviews at W12, 3 month follow-up, and 12 month follow-up. If subject is unable to complete the remaining video-conference assessments, he/she will be asked to complete the same assessment measures via phone.

PROCEDURES

A flow diagram of procedures can be found in Figure 2 of the appendix.

INITIAL INTERNET SCREENING

Participants can be referred by a clinician or self-referred. Participants interested in partaking in the study first do an Internet-administered screening on an encrypted webpage using the BDDQ[58], MADRS-S[47], Alcohol Use Disorders Identification Test (AUDIT)[65], Drug User Disorders Identification Test (DUDIT)[66], DCQ[44], and AAI[45], and filling out general demographic information. Before partaking in the screening, the participant is given written information about the study (objectives, requirements for participation, etc.). Participants will be excluded from the study at this point if they: *a)* score an 8 or higher on the AUDIT, which was found to have sensitivity of 92 % and specificity of 94 % for hazardous and harmful alcohol use[65], *b)* score an 8 or higher on the DUDIT[66], which was found to correspond to impairing drug issues with 90 % sensitivity and 85 % specificity[63], *c)* score at least 5 on item 9 of the MADRS-S[47], *d)* score less than 9 on the DCQ, as 9 was determined to be an optimal cut-off when screening for BDD[44], or *e)* score less than 4 on the BDDQ, as 4 was determined to be an appropriate cut-off for a positive screening of BDD[59].

VIDEO-CONFERENCE INCLUSION/BASELINE ASSESSMENT

If the participant fulfils selection criteria, he/she is interviewed by a psychiatrist/psychologist/supervised Masters level clinician at Karolinska Institutet via video-conference. The aims of this visit are to *a)* discuss informed consent and obtain verbal consent *b)* verify diagnosis of BDD, *c)* assess symptom severity and global functioning, *d)* confirm subject's identity, *e)* evaluate English language competency, *f)* establish a safety plan while in treatment, *g)* assess subject's access to a computer, *h)* obtain subject's treatment history, and *i)* inform patient of treatment protocol. This interview includes the Protocol # XXXX BDD-NET

Informed Consent form (Appendix Figure 3), BDD-YBOCS[41], SCID-5-RV module G[42], M.I.N.I. 7.0[43], BABS[46], C-SSRS Lifetime Recent-Clinical version[48], GAF[50], clinician-rated CGI-S[51], BDD-NET Safety Interview (Appendix Figure 4), and BDD-NET Accessibility and Confidentiality Interview (Appendix Figure 5). Subjects will be evaluated for English language competency via real time conversation during the inclusion evaluation. They will also be asked if English is their native language. If it is not, they will be prompted to read through 1 page of a non-CBT treatment text and to follow prompts to further assess English language proficiency. Additionally, subjects will be asked to hold up a government-issued form of photo identification to confirm name, age, gender, and country of citizenship or residency. During this interview, subjects will be asked about their treatment history related to BDD and mental health concerns.

VIDEO-CONFERENCE INCLUSION/BASELINE ASSESSMENT FOLLOW-UP
Following the video-conference inclusion/baseline assessment, the interviewer will complete an inclusion criteria checklist and review it with a consulting psychiatrist. If the participant meets all criteria for enrolment, he/she will have a follow-up video-conference with a psychiatrist/psychologist/supervised Masters level clinician at Karolinska Institutet in order to *a)* review informed consent and *b)* orient patient to the platform. Participants entered into the study are presented with the informed consent via a secure webpage in order to check yes to consent. Through this webpage, they are then administered baseline assessment measures, including the MADRS-S[47], AAI[45], SPS-R[49], EQ-5D[52], SDS[53], and Credibility/Expectancy Questionnaire[56] prior to beginning treatment.

WEEKLY ASSESSMENTS
Weekly assessments (weeks 1-12) are done in the secure internet platform with the MADRS-S[47], AAI[45], and a form asking about involvement with concomitant medications and/or therapies. Additionally, subjects will be administered the WAI-SR[55] and the Credibility/Expectancy Questionnaire[56] during weeks 2, 4, 6, 8, 10, 12, and post-treatment; the CSI[54] at the beginning of W2 and W7 (mid-treatment), and post-treatment; and the ICBT – EX/RP Adherence Scale weeks 2-12 and post-treatment through the secure platform.

MID-TREATMENT ASSESSMENT
Subjects will be administered the BDD-YBOCS at W6 via video-conference by a psychiatrist/psychologist/Master's level clinician to assess BDD symptom severity.

POST-TREATMENT ASSESSMENT
At post-treatment, a psychiatrist/psychologist/Master's level clinician will administer the same instruments used at the video-conference screening, as well as the CGI-I[51]. Post treatment assessment will also be made via a secure webpage with the MADRS-S[47], DCQ[44], AAI[45], SPS-R[49], WAI-SR[55], ICBT – EX/RP Adherence Scale, and CSI[56]. Additionally, subjects will be asked to complete a treatment feedback form via the internet. If subjects are unable to follow-through with a video-conference evaluation (e.g. no computer access), they will be asked to complete a phone interview containing the same assessment measures.

3-MONTH FOLLOW-UP
A psychiatrist/psychologist/Master's level clinician will administer the BDD-YBOCS[41], SCID-5-RV module G[42], M.I.N.I. 7.0[43], BABS[46], C-SSRS Lifetime Recent-Clinical version[48], GAF[50],

clinician-rated CGI-S[51], and clinician-rated CGI-I[51]. Participants will complete self-ratings via the secure webpage, including the MADRS-S[47], DCQ[44], AAI[45], SPS-R[49], EQ-5D[52], and SDS[53]. If subjects are unable to follow-through with video-conference evaluation (e.g. no computer access), they will be asked to complete a phone interview containing the same assessment measures.

12-MONTH FOLLOW-UP

A psychiatrist/psychologist will administer the same instruments used at video-conference 3-month follow-up. Participants will also complete the same self-ratings as the in the 3-month follow-up via the secure webpage. If subjects are unable to follow-through with video-conference evaluation (e.g. no computer access), they will be asked to complete a phone interview containing the same assessment measures.

MEASURES TO MINIMIZE BIAS

- Prior to subject enrollment, all evaluators will be trained to a reliability criterion (intra-class correlation coefficient (ICC) of at least .85) with a gold-standard rater on the BDD-YBOCS. All video-conferencing inclusion evaluations and post-treatment and 3-month follow-up BDD-YBOCS assessments will be recorded. 10% of videos from each of these assessment points for enrolled subjects will be randomly selected using simple randomization through a true random number service (www.random.org) to be evaluated by a gold-standard rater. If at any point throughout the trial an evaluator's BDD-YBOCS ratings fall below an ICC of .85 with a gold-standard rater, he/she will be retrained to meet this criterion.
- Inclusion evaluators will complete an inclusion criteria checklist for each potential subject and review it with a consulting psychiatrist/psychologist to determine patient suitability for the study prior to enrollment.

TREATMENT

Treatment will utilize an English-language version of the BDD-NET platform employed by Enander, et al. (2015)[40], which uses a hospital server with encrypted traffic and an authentication login function to guarantee participant confidentiality. Treatment starts within seven days after inclusion and is 12 weeks long. BDD-NET incorporates the established CBT techniques of psychoeducation, self-monitoring, cognitive restructuring, exposure with response prevention (EX/RP), and a relapse prevention program. Information in the internet treatment platform is provided in text and divided into 8 modules, with the first 5 containing the core treatment components. Worksheets accompany modules to apply concepts, gather patient information related to symptoms, and monitor EX/RP exercises. Modules 1-4 focus on psychoeducation, functional behavior analyses, cognitive restructuring of meta-cognitions, and individual EX/RP hierarchy formation. Modules 5-8 focus on daily in-vivo EX/RP exercises, monitoring of subjective units of distress (SUDS) levels, and a relapse prevention program. Throughout treatment participants are assigned a psychologist with whom they can communicate through a secure online messaging system. The role of the psychologist is to support patient efforts, trouble-shoot skills applications, and give feedback on written material. Psychologists also use clinical judgement based on each patient's needs and homework completion of each module to grant participants access to subsequent modules[40]. A screen shot of an ICBT platform format can be found in Appendix Figure 6.

CONTINUATION OF TREATMENT

- Patients will not be receiving therapist support beyond W12, but are recommended to continue EX/RP in accordance with the CBT model for BDD.
- Patients will have unlimited access to the BDD-NET platform, including access to all 8 modules, written communications with therapist from W0-W12, and worksheets, but not including ongoing platform communication with a therapist, for 12 months following treatment.
- Referrals will be given to subjects who request them only if the BDD-NET research team is adequately able to provide such recommendations given the location and needs of the patient.

TRIAL TIMETABLE

Goal	Date
Ethical Approval	Jan 2016
Inclusion of First Subject	Feb 2016
Inclusion of Last Subject	Feb 2016
Treatment Completion of Last Subject, first manuscript	May 2016
Last 3-month Follow-up, second manuscript	September 2016
Last 12-month Follow-up, 1-year follow-up manuscript	June 2017

SAFETY

CLINICAL SAFETY ASSESSMENTS

- C-SSRS[48] administration via video-conference will be obtained prior to inclusion to ensure included subjects are at low risk for suicide. It will also be administered at post-treatment and 3 and 12-month follow-up assessments.
- The MADRS-S[47] will be administered via the internet weekly to monitor mood symptoms and suicidal ideations during treatment.
- All platform communications will be monitored by each subject's assigned therapist within 36 hours on weekdays and utilized in clinician risk assessment.
- The AAI[45] will be administered weekly via internet to monitor fluctuations in appearance anxiety.
- Suicidal ideation or risk, as indicated by clinician interview, internet self-report, or platform communication, will be quickly responded to according to a modified version of the Psychiatry Southwest, Stockholm's County Council suicide process (located in Figure 7 of Appendix). This protocol includes criteria for making decisions related to risk and action steps for responding to situations in which sufficient risk is indicated. The main forms of clinician response to further evaluate risk and intervene are reaching out to patients via the secure internet platform, calling, referring subjects to their designated emergency unit, coping skills coaching, developing safety plans, and coordinating services with designated emergency units. Therapists will utilize a safety checklist and structured steps for conducting and responding to risk assessments (Appendix Figure 8). Incidents of risk or suicidal behavior will be documented in patients' medical files, reviewed, and countersigned by a consulting psychiatrist.

PROCEDURES FOR MINIMIZING RISK

- *Informed Consent:* Prior to treatment, subjects will be fully informed of the study procedures, amount of time required of them, and possible benefits and risks of participating in this study. Additionally, they will be advised of the voluntary nature of their participation, their right to refuse participation, and their right to terminate participation at any time. Verbal informed consent will be obtained via video-conference, and subjects will check a box indicating consent in the secure online platform. At request, patients will be sent a paper copy of their informed consent to their mailing address. Subjects will be given the name and telephone number of the Co-Investigator.
- *Confidentiality:* Patients will be notified in the informed consent that all information they provide and all study findings will be kept confidential, with limited access to research staff. All staff involved will be informed of measures to protect patient confidentiality. All communications and handling of protected health information (PHI) will be compliant with standards set forth by the United States Federal Health Information Portability and Accountability Act (HIPAA). This act establishes a number of rules related to ethical healthcare practices and health insurance coverage, including steps for the handling of PHI. Subjects access the secure treatment platform through their internet browsers, and platform data is stored on a KI server running MySQL. This server is owned by Stockholm County Council, and protected by the Swedish data act and Swedish health care laws, as well as the Helsinki declaration. Methods of HIPAA compliance for 4 major areas of privacy are described below.
    1. *Treatment platform access:* Subjects will be given personalized usernames and passwords to access the secure treatment platform.
    2. *Transfer of data in the platform:* Internet communications between subject and therapist will be done via a secure messaging system on a confidential platform. Information entered into the platform through subjects' internet browsers will be sent to the MySQL database at the Stockholm County Council. Data will be transmitted using Secure Socket Layers (SSL) (128 bit encryption), in line with HIPAA security requirements.
    3. *Data storage:* Platform information will be stored behind a Stockholm County Council firewall. Medical records will be stored in the Stockholm County Council TakeCare electronic medical records system. Additionally, certain patient PHI will be kept in a research database on a secure KI server with password encryption.
    4. *Data auditing:* Time points in which data are accessed and parties accessing are tracked by the MySQL system. Only study personnel will have access to patient PHI.
- Video-conferences will be completed using software that is secure and compliant with standards set forth by HIPAA. Video-conference software will be provided by VSee. VSee agreed to sign a Business Associate Agreement stating that their members and employees will not have access to patient videos, will not save patient videos, can provide audit trails of parties viewing videos if asked, and will notify covered entities at KI in the event of a confidentiality breach. Videos between evaluator and patient will not operate through a VSee server, but will require a relay server, likely in patients' home countries, to connect with their computers. If relay servers were to be breached, videos would remain inaccessible, but usernames may not. Therefore, to fully protect PHI and pertinent information, subjects will be assigned a random username composed of digits

and letters that they can log into VSee with. Subjects can download a free version of VSee software and will be covered under KI's Business Associate Agreement with VSee for video-communication with designated parties at KI. Subjects will be advised that they are not covered for VSee communications with outside parties under the VSee-KI Business Associate Agreement. The VSee package used in this study is FIPS-140 level 2 compliant and utilizes 256-bit AES encryption. It also abides by the criteria established in the HIPAA Privacy and Security Rules, as well as the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009.

- Careful pre-treatment assessment to identify and exclude participants who are at high risk for suicide or adverse treatment effects.
    1. Steps for minimizing risk for participants excluded prior to enrollment:
        - Following completion of the initial internet screening, participants will be presented with a form that notifies them when and how they will be contacted by phone if they are eligible for inclusion at this point. This form also includes contact information for the research team and outlines steps for participants to take if they are experiencing acute mental health concerns or do not receive a call within 14 days indicating they are eligible at this point of the study (e.g. visiting an emergency care unit, consulting with mental health specialists). In order to proceed, participants will have to check a box stating that they understand the appropriate steps to take following the initial internet screening.
        - Participants excluded during or after the W0 evaluation or W0 follow-up video-conference will be offered mental health recommendations during these video-conferences as appropriate. Specific types of specialists will be suggested to fit mental health needs. E.g. CBT therapist, licensed psychologist, outpatient care provider with experience treating depression/alcohol abuse/substance abuse, psychiatric consultation, psychiatric evaluation at a local emergency care center. Consultation with emergency care centers and crisis counseling will be offered on the spot if the patient is in imminent risk during the W0 and W0 follow-up video-conferences.
- Monitoring any deterioration of symptoms, adverse treatment effects, and suicidal ideations, and terminating treatment when in the patient's best interest.
    1. Deterioration of anxiety and mood symptoms and suicidal ideations are measured weekly via internet self-report forms. Patients will be contacted via platform or phone call if their MADRS-S[47] item 9 score reaches 4 or higher, or if suicidal ideation or intent is otherwise indicated (e.g. via platform). Deterioration of symptoms will be monitored using the MADRS-S[47] total score and AAI[45] total score. Subjects will be contacted in the event that their MADRS-S[47] and AAI[45] scores increase by 20% of the respective total score ranges. For the MADRS-S[47], deterioration is measured by a 5-point increase, and for the AAI[45], an 8-point increase.
- Offering treatment recommendations and referrals following discontinuation of treatment or treatment withdrawal when a suitable mental health care provider can be located.

- When a subject is withdrawn for reasons related to self-injury or suicidal behaviors, the BDD-NET team will provide ongoing consultation with a designated emergency unit while he/she is stabilized. Additionally, referral options will be offered when feasible.
- Following up completion of the BDD-NET protocol with referrals when patients are interested and a suitable mental health care provider can be located.
- Staff being informed of the modified Psychiatry Southwest, Stockholm County Council's suicide process, and implementing it when suicidal ideation and/or elevated risk of suicide are present.

ADVERSE EVENTS

WHAT IS AN ADVERSE EVENT (AE)?

- Unwanted events caused by treatment (adverse treatment reactions), adverse reactions caused by the correct treatment (side effects), and adverse reactions caused by inappropriate treatment (malpractice effects), will all be considered in the assessment of adverse events.

SERIOUS ADVERSE EVENTS (SAEs)

AEs can be categorized by the investigators as either serious or non-serious. An AE is considered a SAE if it:

- Requires psychiatric hospitalization
- Results in attempt at suicide
- Results in significant deterioration of symptoms or large increase in impairment in daily routines or social or occupational functioning.

PROCEDURES FOR IDENTIFYING AND RESPONDING TO ADVERSE EVENTS

- *Assessment:* AEs will be clinician-evaluated at post-treatment and 3-month follow-up using a checklist by video-conference. AEs will also be assessed weekly using an online adverse events questionnaire. AEs will also be assessed at post-treatment and at 3-month follow-up via video-conference with a clinician.
- *Reporting:* All SAEs or situations in which sufficient risk of a SAE is indicated, as determined by the investigators, will be reported immediately to the Karolinksa Institutet IRB.
- *Responding:* AEs detected by an online weekly adverse events questionnaire will be followed up immediately with a call. In the event that treatment is likely leading to a significant deterioration of symptoms or increased risk of suicide, patients will be withdrawn from treatment. Investigators will offer mental health referrals to patients withdrawn from treatment due to AEs when suitable, appropriate, and feasible. When appropriate, investigators and clinicians will refer patients to emergency care centers and work with them to inform acute treatment.
- *Following up:* Follow-up information regarding the outcome of SAEs and actions taken will be reported to the KI IRB as soon as it's available. The investigators must ensure that actions taken in response to AEs are appropriate to the nature of the event, and that actions continue to be taken until resolution.
- *Documenting:* All AEs will be recorded in KIs TakeCare medical records system. Follow-up information describing the outcome of the SAEs and actions taken will also be recorded in patients' medical records.

QUALITY CONTROL & ETHICS

- The Karolinska Trial Alliance will monitor the study regularly.
- The study will follow Good Clinical Practice (GCP).
- It will be subject to approval of the Regional Ethics Board in Stockholm.
- It will be registered on the ClinicalTrials.gov trial registry.

9. Patient Benefit/Significance for the Health Service

Access to CBT therapists in the United States and elsewhere is limited, and individuals with BDD face substantial barriers to treatment. There is a lack of trained professionals available, face-to-face CBT comes with geographic, financial, and scheduling limitations, and people commonly have difficulty reporting BDD symptoms associated with shame. As a result, too few people with BDD symptoms are left receiving treatments that are not evidence-based, and too often ineffective or harmful. ICBT could start to address these issues, dramatically increasing patient access to evidence-based treatment for BDD. For the individual who cannot afford face to face CBT, does not have a specialized therapist close to home, or has long work hours, BDD-NET can provide a more time flexible option that can be utilized from home. For those who experience shame associated with their appearance and do not want to openly talk about their symptoms and concerns with a therapist face to face, BDD-NET provides another avenue for treatment.

Enander et al. (2014) has shown promising preliminary support for BDD-NET as an efficacious, acceptable, and feasible treatment in Sweden in an uncontrolled pilot study[37]. Enander et al. (2015) then showed BDD-NET to be superior to an active control group in an RCT[40]. If BDD-NET – English version proves to be effective, future directions for research include conducting a larger randomized controlled trial testing the efficacy of this intervention among English-speakers, globally or within certain English-speaking subpopulations and nationalities. Long term goals for this treatment are to either implement it as a part of healthcare systems and private clinics globally, or to continue to treat those with limited access to CBT through the Internet Psychiatry Unit (Internetpsykiatrienheten) at the Stockholm County Council.

10. References

1. American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.
2. Phillips, K. A., Menard, W., Fay, C., & Pagano, M. E. (2005). Psychosocial functioning and quality of life in body dysmorphic disorder. *Comprehensive Psychiatry*, *46*(4), 254-260. http://dx.doi.org/10.1016/j.comppsych.2004.10.004
3. Didie, E. R., Menard, W., Stern, A. P., & Phillips, K. A. (2008). Occupational functioning and impairment in adults with body dysmorphic disorder. *Comprehensive psychiatry*, *49*(6), 561-569. http://dx.doi.org/10.1016/j.comppsych.2008.04.003
4. Phillips, K. A., Menard, W., Quinn, E., Didie, E. R., & Stout, R. L. (2013). A 4-year prospective observational follow-up study of course and predictors of course in body dysmorphic disorder. *Psychological medicine*, *43*(05), 1109-1117. http://dx.doi.org/10.1017/S0033291712001730

5. Phillips, K. A., Coles, M. E., Menard, W., Yen, S., Fay, C., & Weisberg, R. B. (2005). Suicidal ideation and suicide attempts in body dysmorphic disorder. *Journal of Clinical Psychiatry*, *66*(6), 717-725. http://dx.doi.org/10.4088/JCP.v66n0607
6. Phillips, K. A., & Menard, W. (2006). Suicidality in body dysmorphic disorder: a prospective study. *American Journal of Psychiatry*, *163*(7), 1280-1282. http://dx.doi.org/10.1176/appi.ajp.163.7.1280
7. Buhlmann, U., Glaesmer, H., Mewes, R., Fama, J. M., Wilhelm, S., Brähler, E., & Rief, W. (2015). Updates on the Prevalence of Body Dysmorphic Disorder: A Population-Based Survey. *Focus*, *13*(2), 252-257. http://dx.doi.org/10.1176/appi.focus.130217
8. Koran, L. M., Abujaoude, E., Large, M. D., & Serpe, R. T. (2008). The prevalence of body dysmorphic disorder in the United States adult population. *CNS spectrums*, *13*(04), 316-322.
9. Brohede, S., Wingren, G., Wijma, B., & Wijma, K. (2015). Prevalence of body dysmorphic disorder among Swedish women: A population-based study. *Comprehensive psychiatry*, *58*, 108-115. http://dx.doi.org/10.1016/j.comppsych.2014.12.014
10. Otto, M. W., Wilhelm, S., Cohen, L. S., & Harlow, B. L. (2001). Prevalence of body dysmorphic disorder in a community sample of women. *Prevalence*, *158*(12).
11. Vinkers, D. J., Van Rood, Y. R., & Van der Wee, N. J. (2007). Prevalence and comorbidity of body dysmorphic disorder in psychiatric outpatients. *Tijdschrift voor psychiatrie*, *50*(9), 559-565.
12. Bartsch, D. (2007). Prevalence of body dysmorphic disorder symptoms and associated clinical features among Australian university students. *Clinical Psychologist*, *11*(1), 16-23. http://dx.doi.org/10.1080/13284200601178532
13. Monzani, B., Rijsdijk, F., Anson, M., Iervolino, A. C., Cherkas, L., Spector, T., & Mataix-Cols, D. (2012). A twin study of body dysmorphic concerns. *Psychological medicine*, *42*(09), 1949-1955.
14. Kollei, I., Martin, A., Rein, K., Rotter, A., Jacobi, A., & Mueller, A. (2011). Prevalence of body dysmorphic disorder in a German psychiatric inpatient sample. *Psychiatry research*, *189*(1), 153-155. http://dx.doi.org/10.1016/j.psychres.2011.02.009
15. Grant, J. E., Kim, S. W., & Crow, S. J. (2001). Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. *The Journal of clinical psychiatry*, *62*(7), 517-522.
16. Crerand, C. E., Phillips, K. A., Menard, W., & Fay, C. (2005). Nonpsychiatric medical treatment of body dysmorphic disorder. *Psychosomatics*, *46*(6), 549-555. http://dx.doi.org/10.1176/appi.psy.46.6.549
17. Phillips, K. A., Grant, J., Siniscalchi, J., & Albertini, R. S. (2001). Surgical and nonpsychiatric medical treatment of patients with body dysmorphic disorder. *Psychosomatics*, *42*(6), 504-510. http://dx.doi.org/10.1176/appi.psy.46.6.549
18. Sarwer, D. B., Crerand, C. E., & Didie, E. R. (2003). Body dysmorphic disorder in cosmetic surgery patients. *Facial plastic surgery: FPS*, *19*(1), 7-18.
19. Ipser, J. C., Sander, C., & Stein, D. J. (2009). Pharmacotherapy and psychotherapy for body dysmorphic disorder. *The Cochrane Library*. http://dx.doi.org/10.1002/14651858.CD005332.pub2
20. Williams, J., Hadjistavropoulos, T., & Sharpe, D. (2006). A meta-analysis of psychological and pharmacological treatments for body dysmorphic disorder. *Behaviour Research and Therapy*, *44*(1), 99-111. http://dx.doi.org/10.1016/j.brat.2004.12.006

21. Wilhelm, S., Phillips, K. A., Didie, E., Buhlmann, U., Greenberg, J. L., Fama, J. M., ... & Steketee, G. (2014). Modular cognitive-behavioral therapy for body dysmorphic disorder: a randomized controlled trial. *Behavior therapy*, *45*(3), 314-327. http://dx.doi.org/10.1016/j.beth.2013.12.007
22. Veale, D., Anson, M., Miles, S., Pieta, M., Costa, A., & Ellison, N. (2014). Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: a randomised controlled trial. *Psychotherapy and psychosomatics*, *83*(6), 341-353. http://dx.doi.org/10.1159%2F000360740
23. Wilhelm, S., Phillips, K. A., Fama, J. M., Greenberg, J. L., & Steketee, G. (2011). Modular cognitive–behavioral therapy for body dysmorphic disorder. *Behavior Therapy*, *42*(4), 624-633.
24. Buhlmann, U. (2011). Treatment barriers for individuals with body dysmorphic disorder: An Internet survey. *Journal of Nervous and Mental Disease*, *199*(4), 268-271. http://dx.doi.org/10.1097/NMD.0b013e31821245ce
25. Marques, L., Weingarden, H. M., LeBlanc, N. J., & Wilhelm, S. (2011). Treatment utilization and barriers to treatment engagement among people with body dysmorphic symptoms. *Journal of psychosomatic research*, *70*(3), 286-293. http://dx.doi.org/10.1016/j.jpsychores.2010.10.002
26. Cavanagh, K. (2014). Geographic inequity in the availability of cognitive behavioural therapy in England and Wales: a 10-year update. *Behavioural and cognitive psychotherapy*, *42*(04), 497-501. http://dx.doi.org/10.1017/S1352465813000568
27. Mojtabai, R. (2005). Trends in contacts with mental health professionals and cost barriers to mental health care among adults with significant psychological distress in the United States: 1997–2002. *American Journal of Public Health*, *95*(11), 2009-2014.
28. Cuijpers, P., van Straten, A., & Andersson, G. (2008). Internet-administered cognitive behavior therapy for health problems: a systematic review. *Journal of behavioral medicine*, *31*(2), 169-177. http://dx.doi.org/10.1007/s10865-007-9144-1
29. Andersson, E., Enander, J., Andrén, P., Hedman, E., Ljótsson, B., Hursti, T., ... & Rück, C. (2012). Internet-based cognitive behaviour therapy for obsessive–compulsive disorder: a randomized controlled trial. *Psychological medicine*, *42*(10), 2193-2203. http://dx.doi.org/10.1017/S0033291712000244
30. Hedman, E., Ljótsson, B., & Lindefors, N. (2012). Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost-effectiveness. Expert Rev Pharmacoecon Outcomes Res 2012;12:745–64.
31. Wootton, B. M., Dear, B. F., Johnston, L., Terides, M. D., & Titov, N. (2013). Remote treatment of obsessive-compulsive disorder: a randomized controlled trial. *Journal of Obsessive-Compulsive and Related Disorders*, *2*(4), 375-384. http://dx.doi.org/10.1016/j.jocrd.2013.07.002
32. Andersson, G., Cuijpers, P., Carlbring, P., Riper, H., & Hedman, E. (2014). Guided Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis. *World Psychiatry*, *13*(3), 288-295. http://dx.doi.org/10.1002/wps.20151
33. Hedman, E. (2014). Therapist guided internet delivered cognitive behavioural therapy. *BMJ*, *348*.
34. Hedman, E., Ljótsson, B., Kaldo, V., Hesser, H., El Alaoui, S., Kraepelien, M., ... & Lindefors, N. (2014). Effectiveness of Internet-based cognitive behaviour therapy for

depression in routine psychiatric care. *Journal of affective disorders*, *155*, 49-58.
35. Ruwaard, J., Lange, A., Schrieken, B., Dolan, C. V., & Emmelkamp, P. (2012). The effectiveness of online cognitive behavioral treatment in routine clinical practice. *PLoS One*, *7*(7), e40089.
36. Williams, A. D., Andrews, G., & Andersson, G. (2013). The effectiveness of Internet cognitive behavioural therapy (iCBT) for depression in primary care: a quality assurance study. *PLoS One*, *8*(2), e57447.
37. Enander, J., Ivanov, V. Z., Andersson, E., Mataix-Cols, D., Ljótsson, B., & Rück, C. (2014). Therapist-guided, Internet-based cognitive–behavioural therapy for body dysmorphic disorder (BDD-NET): a feasibility study. *BMJ open*, *4*(9), e005923. http://dx.doi.org/10.1136/bmjopen-2014-005923
38. Wilhelm, S., Phillips, K. A., & Steketee, G. (2013). A cognitive-behavioral treatment manual for body dysmorphic disorder. *New York: Guilford*.
39. Veale, D., & Neziroglu, F. (2010). *Body dysmorphic disorder: A treatment manual*. John Wiley & Sons.
40. Enander, Jesper, Andersson, Erik, Mataix-Cols, David, Lichtenstein, Linn, Alström, Katarina, Andersson, Gerhard, Ljótsson, Brjánn, Rück, Christian (2015). Therapist-guided Internet-based cognitive behavioural therapy for body dysmorphic disorder: A single-blind randomised controlled trial and cost-effectiveness study. Manuscript submitted for publication. Department of Clinical Neuroscience, Karolinksa Universitet, Stockholm, Sweden.
41. Phillips, K. A., Hart, A. S., & Menard, W. (2014). Psychometric evaluation of the Yale–Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS). *Journal of Obsessive-Compulsive and Related Disorders, 3*(3), 205-208. http://dx.doi.org/10.1016/j.jocrd.2014.04.004
42. First MB, Williams JBW, Karg RS, Spitzer RL: Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA, American Psychiatric Association, 201547.
43. Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., ... & Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of clinical psychiatry, 59, 22-33.
44. Oosthuizen, P., Lambert, T., & Castle, D. J. (1998). Dysmorphic concern: prevalence and associations with clinical variables. *Australian and New Zealand Journal of Psychiatry, 32*(1), 129-132.
45. Veale, D., Eshkevari, E., Kanakam, N., Ellison, N., Costa, A., & Werner, T. (2014). The Appearance Anxiety Inventory: Validation of a process measure in the treatment of body dysmorphic disorder. *Behavioural and cognitive psychotherapy*, *42*(05), 605-616.
46. Eisen, J. L., Phillips, K. A., Baer, L., Beer, D. A., Atala, K. D., Rasmussen, S. A. (1998). The Brown Assessment of Beliefs Scale: Reliability and validity. *The American Journal of Psychiatry, 155*(1), 102-108. http://dx.doi.org/10.1176/ajp.155.1.102
47. Svanborg, P., & Åsberg, M. (1994). A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. *Acta Psychiatrica Scandinavica, 89*(1), 21-28.
48. Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., ... & Mann, J. J. (2011). The Columbia–Suicide Severity Rating Scale: initial validity and

internal consistency findings from three multisite studies with adolescents and adults. *American Journal of Psychiatry*.
49. Snorrason, I., Olafsson, R. P., Flessner, C. A., Keuthen, N. J., Franklin, M. E., & Woods, D. W. (2012). The skin picking scale-revised: factor structure and psychometric properties. *Journal of Obsessive-Compulsive and Related Disorders, 1*(2), 133-137.
50. American Psychiatric Association (2000). *Diagnostic and statistical manual of mental disorders* (4th ed., Text Revision): DSM-IV-TR. Washington, DC: American Psychiatric Association.
51. Guy, W. (1976). National Institute of Mental Health (US). Psychopharmacology research branch, early clinical drug evaluation program. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Dept. of Health, Education, and Welfare. *Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs*.
52. Rabin, R. and F.d. Charro, (2001). EQ-SD: a measure of health status from the EuroQol Group. *Annals of Medicine*, *33*(5), 337-343.
53. Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997). Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. *The international journal of psychiatry in medicine*, *27*(2), 93-105.
54. McMurtry, S. L., & Hudson, W. W. (2000). The Client Satisfaction Inventory: Results of an initial validation study. *Research on Social Work Practice*, *10*(5), 644-663.
55. Hatcher, R. L., & Gillaspy, J. A. (2006). Development and validation of a revised short version of the Working Alliance Inventory. *Psychotherapy Research*, *16*(1), 12-25.
56. Devilly, G. J., & Borkovec, T. D. (2000). Psychometric properties of the credibility/expectancy questionnaire. *Journal of behavior therapy and experimental psychiatry*, *31*(2), 73-86.
57. Simpson, H. B., Maher, M., Page, J. R., Gibbons, C. J., Franklin, M. E., & Foa, E. B. (2010). Development of a patient adherence scale for exposure and response prevention therapy. *Behavior therapy*, *41*(1), 30-37.
58. Phillips, K. A. (1996). Instruments for assessing BDD: The BDDQ: A self-report screening instrument for BDD. *The broken mirror*, 321-333.
59. Brohede, S., Wingren, G., Wijma, B., & Wijma, K. (2013). Validation of the Body Dysmorphic Disorder Questionnaire in a community sample of Swedish women. *Psychiatry research*, *210*(2), 647-652.
60. Mancuso, S. G., Knoesen, N. P., & Castle, D. J. (2010). The Dysmorphic Concern Questionnaire: A screening measure for body dysmorphic disorder. *Australian and New Zealand Journal of Psychiatry*, *44*(6), 535-542. http://dx.doi.org/10.3109/00048671003596055
61. Fantino, B., Moore, N., (2009). The self-reported Montgomery-Åsberg depression rating scale is a useful evaluative tool in major depressive disorder. BMC Psychiatry. 9(26). http://dx.doi.org/10.1186/1471-244X-9-26
62. Svanborg, P. and M. Asberg, A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J Affect Disord, 2001. 64(2-3): p. 203-16.

63. Holländare, F., Andersson, G., & Engström, I. (2010). A comparison of psychometric properties between internet and paper versions of two depression instruments (BDI-II and MADRS-S) administered to clinic patients. Journal of medical Internet research, 12(5).
64. Brooks, R., & Group, E. (1996). EuroQol: the current state of play. *Health policy*, *37*(1), 53-72.
65. Saunders, J. B., Aasland, O. G., Babor, T. F., De la Fuente, J. R., & Grant, M. (1993). Development of the alcohol use disorders identification test (AUDIT). WHO collaborative project on early detection of persons with harmful alcohol consumption-II. ADDICTION-ABINGDON-, 88, 791-791.
66. Voluse, A. C., Gioia, C. J., Sobell, L. C., Dum, M., Sobell, M. B., & Simco, E. R. (2012). Psychometric properties of the Drug Use Disorders Identification Test (DUDIT) with substance abusers in outpatient and residential treatment. *Addictive Behaviors*, *37*(1), 36-41. http://dx.doi.org/10.1016/j.addbeh.2011.07.030

Appendix

Figure 1. Early Termination Checklist

Reason(s) for Early Treatment Termination (Check all that apply):

Specify details of early termination in comments below

Reason	Comments
Need for higher level of care (e.g. hospitalization)	
Current clinically significant suicidality and/or MADRS-S suicide item (Q9) score ≥ 5	
PI decision	
Lost to follow-up	
Experienced NSAE	
Experienced SAE	
Protocol Violation	
Life Circumstances	
Treatment No Longer Needed	
Patient Not Willing to Continue	
Time commitment too great	
Noncompliance with protocol	
Voluntary withdrawal due to not enough time/other priorities (subject report)	
Voluntary withdrawal due to treatment not right fit (subject report)	
Voluntary withdrawal due to problems with treatment itself (subject report)	Problems:
Voluntary withdrawal Other (subject report)	
Other	

Figure 2. Flow Diagram of Procedures



Figure 3. Informed Consent Form

Department of Clinical Neuroscience

Informed Consent Form

Therapist Guided, Internet-based Cognitive Behavioral Therapy for Body Dysmorphic Disorder – English Version (BDD-NET): A Feasibility Study

You have expressed interest in participating in this study at BDDstudy.com.

Objectives of this study
There is evidence to support that cognitive behavioral therapy (CBT) may be an effective treatment for people with body dysmorphic disorder (BDD). However, global access to specialized CBT therapists is very limited. Internet-based CBT (ICBT) has been developed, showing promising evidence as an effective treatment for BDD, but is currently only available in Sweden. Karolinska Institutet (Sweden) is conducting this study in order to investigate the efficacy and feasibility of CBT for BDD administered through a global internet platform.

Methods used and why they are used
In order to participate in the project, you must meet pre-determined criteria for body dysmorphic disorder and not suffer from other serious psychiatric problems, such as bipolar disorder. This is assessed by a diagnostic interview via video-conference where you will have to answer questions about body dysmorphic disorder and other psychiatric conditions. Video-conference assessments will generally take approximately 90 minutes. Minimum age for participation is 18 years. In order for us to be able to evaluate the results of treatment you will be given various questionnaires before, during, and after treatment. You will be contacted for video-conference evaluations once during treatment, immediately after completing treatment, and 3 and 12-months after completing treatment.

Internet treatment consists of a self-help program with therapist support via e-mail. ICBT has shown to be effective for treating a number of disorders, and the current treatment is based on proven CBT principles. The name of this treatment program is BDD-NET – English version. It is in English only and fully available through the internet.

Treatment is free of charge.

Participation
To be considered for this study, it is required that you have access to an internet connected computer, that you have the opportunity to work with the material for at least six hours per week, and that you are fully fluent in English, including reading, writing, and speaking. All participants will receive 12 weeks of treatment.

Participation is completely voluntary. You can choose not to participate and you can cancel participation at any time, for any reason, without having to disclose the reason, and without penalty. Your participation will not affect your ability to get other care. You will be able to take part in the results in the form of a scientific publication, but will not see your own results.

Duration of participation
Treatment lasts for twelve weeks. Video-conference interviews will be conducted before, during, and after the completion of treatment, as well as three and twelve months after treatment. The treatment will take about 6 hours per week.

Privacy and Confidentiality
All results of surveys, questionnaires, and interviews, as well as private or personal information provided to BDD-NET research personnel by participants in this study will be treated as confidential. The continued scientific processing of the information gathered from surveys, questionnaires, interviews, and communications with therapists will be done without identifying information of patients. The primary person held responsible for this is Associate Professor Christian Rück at Karolinska Institutet.

All information you provide is protected under Swedish secrecy and privacy regulations. Additionally, the current study has taken steps to by fully compliant with the United States federal Health Information Portability and Accountability Act (HIPAA) Privacy and Security Rules, as well as the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009. Protected Health Information (PHI) will be protected in accordance with these legislations for all forms of communication with study personnel, including all access, storage, transfer, and auditing of private and personal information.

HIPAA Privacy Rule: http://www.hhs.gov/ocr/privacy/hipaa/administrative/privacyrule/index.html
HIPAA Security Rule: http://www.hhs.gov/ocr/privacy/hipaa/administrative/securityrule/index.html
HITECH Act of 2009:
http://www.hhs.gov/ocr/privacy/hipaa/administrative/enforcementrule/hitechenforcementifr.html

This study will utilize secure video-conference technology to conduct assessments. Please note that information transmitted with this technology is only secure for communications with designated research personnel at Karolinksa Institutet. The use of this technology to contact other parties is not protected or confidential according to HIPAA standards.

The Swedish Personal Data Act (PUL)
Study information will be housed at Stockholm County Hospital (Healthcare Provision) in ongoing computer research databases. The responsible party for this information is the registry's Data Protection Officer, who can be contacted regarding data concerns: PO Box 179 14, 118 95 STOCKHOLM; phone: +46 8-123400 00. No one except the researchers involved in this project will be able to see your personal information. If you want find out what information is held about you, you can request this in writing directly to Stockholm County Council (contact details above). You are entitled to receive this information once per year at no cost. If you identify incorrect information about you, it can be corrected. After 15 years the data Passkey will be destroyed. Then it will no longer be possible to disclose any records.

Contact for further information:

- Christopher La Lima, co-investigator and project manager, XXXX (long distance charges may apply), Email: christopher.la.lima@ki.se
- Christian Rück, principal investigator, assistant professor, Email: christian.ruck@ki.se

Consent participation

I do not wish to participate in the BDD-NET treatment study
I do wish to participate in the BDD-NET treatment study

I ..... have taken note of the above written information on the implementation of the study and what participation means. I consent to the processing of personal data as described above. I am aware that my participation is voluntary and that I, at any time, and without explanation, have the right to cancel my participation without penalty.

Location .....

Date .....

Name (Printed) .....

Signed .....

Figure 4. BDD-NET Safety Plan

BDD-NET Safety Plan

Information for 24-hour psychiatric emergency center: (look up suggested centers based on location ahead of time and call to confirm they provide such services)

Phone number:

_____

(Fill out prior to interview)

Address/Location:

_____

(Fill out prior to interview)

Information for Alternative Emergency Center if Requested:

Phone number:

_____

Address/Location:

_____

Name of Emergency Contact Person/Next of Kin who can be contacted in the event of emergency:

_____

Emergency Contact Person's phone number:

_____

Figure 5. BDD-NET Accessibility and Confidentiality Interview

BDD-NET Accessibility and Confidentiality Interview

- Do you have access to computer with internet access at least once per day for 1 hour or more?

_____

- Where is this computer located?

_____

- Do you have a private email account where you can be notified of updates in the ICBT platform? (Please write below:)

_____

- Please choose a personalized password for access to your ICBT account:

_____

Figure 6. Screen Shot of an ICBT Treatment Platform


Internetpsykiatri.se
https://www.internetpsykiatri.se/dev/Treatment.php?state|5686|page=q&statebranch=23&stateposition=1
Menu
Welcome
Modules
General
Module 1: Introduction
Module 2: A CBT model of OCD
Module 3: Thinking mistakes in OCD
Module 4: Introduction to ERP
Module 5: More about ERP
Module 6: Imaginal exposure
Module 7: Re-exposure
Module 8: Difficulties during the treatment
Module 9: Long term goals and values
Module 10: Summary and Wrap Up
Contact Therapist
Participant editor
Log out
Logged in as Eriktest. Time 2:24
Back to therapist view
Module 4: Introduction to ERP > Homework
Print
Homework Tasks: Module 4
1. Fill in the "Goal worksheet" form, found in the worksheet/documents section located on the right corner of your screen.. NOTE: Don't start practicing exposures and ritual prevention yet. You'll do that in collaboration with your therapist.
2. Use the "My Exposure Hierarchy" worksheet to construct your own exposure hierarchy.
3. Answer the following questions:
A. What is exposure and ritual prevention (ERP)?
B. Why is it important not to use rituals when you expose yourself to something that causes anxiety and distress?
Module navigation
Content
Module 4: Introduction to Exposure and Ritual Prevention
What is exposure and ritual prevention?
Doing exposure and ritual prevention (ERP)
Different ways to do ritual prevention
Guidelines for ritual prevention and "normal behavior"
Designing your personal treatment plan
Homework
Worksheet/document
Worksheets
OCD diary
The CBT model
Interpretation errors
Goal worksheet
Exposure hierarchy
Document viewer
Emergency phone number
Therapist e-mail contact
Self-help text
Navigation
Worksheets

Figure 7. Suicide Process



Psykiatri Sydväst
STOCKHOLMS LÄNS LANDSTING

Suicide Process 2: Patient Doesn't Answer Phone



Psykiatri Sydväst
STOCKHOLMS LÄNS LANDSTING

Suicide Process 3: Phone Contact Made, Acute Risk

Responsible: Löl Cecilia Svanborg



Figure 8. Therapist Safety Checklist and Tools for Crisis Coaching

STEPS

Example of suggested transition to risk conversation:

- I appreciate how difficult this problem must be for you at this time. Some of my patients with similar problems/symptoms have told me that they have thought about ending their life. I wonder if you have had similar thoughts?

When risk is indicated, follow…

SUICIDAL RISK ASSESSMENT CHECKLIST:

- Are you feeling hopeless about the present or future? _____

  If yes ask…
- Have you had thoughts about taking your life? _____

  If yes ask…
- When did you have these thoughts and do you have a plan to take your life? _____

_____

  If yes, inquire about plan: _____

_____

- Have you begun to carry out your plan? _____

- Are there any reasons you would not make a suicide attempt (pt may say not fair to family, religious values, etc.)? Look for protective factors here: _____

_____

- Have you ever had a suicide attempt? _____

  Before getting off phone, ask…
- Are you in any physical harm? _____

- Can you keep yourself safe for the next hour? _____

- " for the next day? _____

- " for the next week? _____

- " for the next month? _____

RESPONDING

If pt is **escalated and/or demonstrates imminent risk** of self-harm (SI or suicide) in same day, de-escalate and create a safer environment with the following steps:

- **Remove or secure any lethal means of self-harm** (e.g. weapons, pills)
- **Decrease isolation** (can be designated emergency contact)
- **Decrease anxiety and agitation**
    - E.g. paced breathing (5 seconds in, hold 1, 5 seconds out, or longer/shorter as pt is comfortable).
    - Progressive Muscle Relaxation (PMR)
    - Listen, allow expression of feelings
    - Being accepting and non-judgmental
    - Speak directly, openly, and matter-of-factly about suicide and your current concerns
    - Offer hope that there are alternatives available, but don't reassure that any 1 strategy will turn things around right away
- **Engage patient in a safety plan** (crisis management or contingency planning), with steps for follow-through. Can involve family members and others.
    - If pt feels the need to self-harm, what are his/her go-to coping strategies, distress tolerance skills, and replacement behaviors?
        - E.g. Paced breathing, diaphragmatic breathing, music, sensory behaviors for 5 senses (scented lotions/soaps, bubble bath, touching something textured), PMR, splash face w/ very cold water (drops heart rate to resting pace), 10 minutes of intense exercise, opposite emotion activity: e.g. watching a TV or YouTube video that is incompatible with current emotion (e.g. if sad, watch comedy), reach out to a friend or family member
    - In the future, should feelings of hopelessness or urges to self-harm or engage in suicidal behaviors occur, how will the pt keep him/herself safe?
        - Knowing who to reach out to and when: EU when formal assessment indicated or in risk of harm (*preferred bc they can work w/ pt in person), BDD-NET therapist or PI if in risk of harm, family and friends for social support.
        - When in risk of harm, keep reaching out until EU, therapist, or PI is reached, and notify therapist or PI when you can. If these parties cannot be reached right away, seek social support from emergency contact person or in appropriate ways until designated parties are reached.
    - Obtain agreement on this Safety Contract for designated amount of time depending on risk. E.g. can you agree to follow these steps for the next week?
    - You can recap the decided on contract in the platform.
    - Once safety plan and skills are agreed upon by the patient and therapist, remind patient to use the skills.
- **Reinforce all safe and healthy behaviors** of the patient along the way. E.g. you're doing a great job sticking with paced breathing and leading it on your own.

FOLLOWING CRISIS COUNSELING

- If sufficient patient risk is indicated, prompt him/her to receive a formal assessment at the designated EU. Follow procedures on Suicide Process 3.
- If patient is at low risk and not in need of EU, follow procedures on Suicide Process 1.

THERAPIST SELF-CARE

- Seek support for yourself when you feel you've been emotionally affected.

http://www.mentalhealth.va.gov/docs/suicide_risk_assessment_guide.doc
http://www.vbh-pa.com/provider/info/qual_mgt/Summary_and_Review_APA_Suicide_Guidelines_Review.pdf
http://www.apa.org/ethics/code/

Supplementary References

1 Veale D, Eshkevari E, Kanakam N, *et al.* The Appearance Anxiety Inventory: validation of a process measure in the treatment of body dysmorphic disorder. *Behav Cogn Psychother* 2014;**42**:605–16. doi:10.1017/S1352465813000556

2 Eisen JL, Phillips KA, Baer L, *et al.* The Brown Assessment of Beliefs Scale: reliability and validity. *Am J Psychiatry* 1998;**155**:102–8. doi:10.1176/ajp.155.1.102

3 Brooks R. EuroQol: the current state of play. *Health Policy* 1996;**37**:53–72.https://www.ncbi.nlm.nih.gov/pubmed/10158943

4 Rabin R, Charro F de. EQ-SD: a measure of health status from the EuroQol Group. *Ann Med* 2001;**33**:337–43. doi:10.3109/07853890109002087

5 Sheehan DV. Sheehan disability scale. In: Rush J, First MB, Blacker D, eds. *Handbook of psychiatric measures*. Washington DC: : American Psychiatric Association 2008. 100–2.

6 Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. *Int Clin Psychopharmacol* 1996;**11 Suppl 3**:89–95.https://www.ncbi.nlm.nih.gov/pubmed/8923116

7 Snorrason I, Ólafsson RP, Flessner CA, *et al.* The Skin Picking Scale-Revised: Factor structure and psychometric properties. *J Obsessive Compuls Relat Disord* 2012;**1**:133–7. doi:10.1016/j.jocrd.2012.03.001

8 Simpson HB, Maher M, Page JR, *et al.* Development of a patient adherence scale for exposure and response prevention therapy. *Behav Ther* 2010;**41**:30–7. doi:10.1016/j.beth.2008.12.002